Literature DB >> 2107018

Cerebrospinal fluid pressure and prolactin in empty sella syndrome.

G Maira1, C Anile, L De Marinis, A Mancini, A Barbarino.   

Abstract

In 58 female patients with the primary empty sella (PES) syndrome, a study of the CSF dynamics was done by evaluating both the absorptive reserve by a lumbar infusion test at constant rate, and/or the ICP increase occurring during REM phase of nocturnal physiological sleep. In 33, prolactin (PRL) dynamics were also investigated evaluating both the response to sequential stimulating test with thyrotropin-releasing hormone (TRH) and metoclopramide (MCP) and/or the circadian variation of PRL levels. Impairment of CSF dynamics was found in the 84% who had a hormonal pattern characterized by an increase of the PRL response to TRH and MCP and a decrease of the PRL circadian variation. Twenty-one patients with impaired CSF dynamics underwent CSF shunting procedures with disappearance of the signs of intracranial hypertension. They also had restoration of normal PRL dynamics but the endocrine alterations improved only moderately. Altered CSF dynamics play a role in the pathogenesis of the PES syndrome. A correlation between elevated ICP and the hypothalamo-hypophyseal control of PRL secretion may exist.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107018     DOI: 10.1017/s0317167100030122

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  2 in total

Review 1.  Primary empty sella: Why and when to investigate hypothalamic-pituitary function.

Authors:  A Giustina; G Aimaretti; M Bondanelli; F Buzi; S Cannavò; S Cirillo; A Colao; L De Marinis; D Ferone; M Gasperi; S Grottoli; T Porcelli; E Ghigo; E degli Uberti
Journal:  J Endocrinol Invest       Date:  2010-03-05       Impact factor: 4.256

2.  TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome.

Authors:  P Valensi; M E Combes; G Perret; J R Attali
Journal:  J Endocrinol Invest       Date:  1996-05       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.